Friday, October 10, 2025
HomeTagsLiver and cardiometabolic diseases

liver and cardiometabolic diseases

Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy

Roche, announced that it has entered into a definitive merger agreement to acquire 89bio, a publicly listed clinical-stage biopharmaceutical company pioneering the development of...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics